TMEM67 Antibody

What is TMEM67 and why is it important in research?

TMEM67 is a transmembrane protein with 995 amino acid residues and a mass of 111.7 kDa in humans. It functions as a component of the MKS module in the ciliary transition zone, forming part of the transition zone "necklace" that anchors the ciliary membrane to the microtubule core and creates a functional diffusion barrier . The protein contains an N-terminal extracellular cysteine-rich domain (CRD) homologous to Frizzled family receptors, enabling it to bind Wnt ligands and modulate non-canonical Wnt signaling pathways .

TMEM67 is widely expressed in both adult and fetal tissues, with subcellular localization primarily in the cell membrane, endoplasmic reticulum, and cytoplasm . Its research significance stems from its dual functionality in ciliary structure maintenance and Wnt signaling, making it crucial for understanding ciliopathies like Meckel-Gruber syndrome and Joubert syndrome .

What applications are TMEM67 antibodies most commonly used for?

TMEM67 antibodies are utilized across multiple experimental applications, with Western Blot being the most widely reported technique in research publications . Other common applications include:

• Immunocytochemistry (ICC) and Immunofluorescence (IF): For visualizing TMEM67 localization in cultured cells, particularly at the ciliary transition zone and cell membrane .

• Immunohistochemistry (IHC): For detecting TMEM67 expression in tissue sections, including both paraffin-embedded (IHC-p) and frozen sections (IHC-fr) .

• ELISA: For quantitative analysis of TMEM67 expression in biological samples .

When selecting an antibody for a particular application, researchers should verify that the antibody has been validated for that specific use, as performance can vary significantly between applications .

How should I optimize fixation methods for TMEM67 immunostaining?

Fixation methods significantly impact TMEM67 antibody detection, with different cellular components requiring specific approaches:

For transition zone-specific markers and TMEM67 in this context, ice-cold methanol fixation for 5 minutes at -20°C is recommended . Methanol fixation exposes transition zone epitopes that might be masked with paraformaldehyde alone.

After fixation, washing three times in PBST followed by blocking in 5% normal goat serum in PBST for 1 hour at room temperature optimizes signal-to-noise ratio . Primary and secondary antibodies should be diluted in the same blocking solution to minimize non-specific binding.

Which model systems are most appropriate for TMEM67 antibody validation?

Several model systems have been developed that can serve as essential controls for validating TMEM67 antibodies:

• Cell lines: TMEM67 knockout RPE-1 cells provide an excellent negative control for antibody specificity testing . Wild-type hTERT-RPE-1 cells serve as positive controls, especially after serum starvation to induce ciliogenesis .

• Mouse models: Multiple transgenic mouse models exist, including Tmem67 ΔCLE/ΔCLE and Tmem67 (C57BL/6NJ- +/− Tmem67 /Mmjax) em1(IMPC)J, which can be used to validate antibody specificity in tissues .

• Primary cells: Mouse embryonic fibroblasts (MEFs) harvested from E13.5 embryos of wild-type and Tmem67 mutant mice can be cultured and used for antibody validation in a primary cell context .

When validating a new TMEM67 antibody, incorporating at least one knockout system is critical to confirm specificity and rule out cross-reactivity with other proteins.

How can I differentiate between the cleaved and non-cleaved forms of TMEM67 using antibodies?

Recent research has revealed that TMEM67 exists in two functional forms governed by ADAMTS9-mediated proteolytic cleavage in the extracellular domain . To distinguish between these forms:

• Epitope selection: Choose antibodies targeting epitopes on either side of the cleavage sites. Antibodies recognizing the N-terminal extracellular domain will detect the full-length non-cleaved form, while those targeting the C-terminal portion will detect both the cleaved and non-cleaved forms .

• Western blot analysis: Run samples under non-reducing and reducing conditions to preserve or disrupt potential disulfide bonds that might maintain association between cleaved fragments. This approach reveals distinctive molecular weight bands representing the different forms .

• Comparative analysis: Use ADAMTS9 knockout cells alongside wild-type cells to analyze the distribution pattern of TMEM67. In ADAMTS9-deficient cells, you should observe accumulation of the non-cleaved form, while in wild-type cells, both forms should be present .

• Domain-specific constructs: As experimental controls, use the TMEM67 Δ342 and N-331 constructs which represent the cleaved portions, helping to validate antibody recognition patterns .

What considerations should be made when studying TMEM67's dual roles in cilia formation and Wnt signaling?

TMEM67 uniquely participates in both ciliary transition zone assembly and non-canonical Wnt signaling, presenting specific experimental challenges:

For ciliary transition zone studies:

• Focus on the C-terminal portion of TMEM67 which localizes to the ciliary transition zone and regulates ciliogenesis .

• Use serum starvation (24 hours) to induce ciliogenesis in cultured cells before antibody staining .

• Co-stain with axoneme markers (acetylated α-tubulin) and basal body markers (γ-tubulin) to precisely locate TMEM67 within the ciliary structure .

For Wnt signaling studies:

• Focus on the non-cleaved form containing the CRD domain that interacts with Wnt5a and ROR2 .

• Use L-Wnt5A or L-Wnt3A conditioned media to stimulate signaling pathways before analyzing TMEM67 interactions .

• Consider ROR2 phosphorylation as a readout for TMEM67-mediated non-canonical Wnt signaling activation .

For differential analysis:

• The Tmem67 ΔCLE/ΔCLE mouse model offers a unique tool as it is defective for ciliogenesis but maintains normal Wnt signaling, allowing separation of these two functions .

• When using antibodies for co-immunoprecipitation, select those that recognize epitopes unlikely to be involved in protein-protein interactions to avoid interference .

How can mutations in TMEM67 affect antibody recognition and experimental design?

Several ciliopathy-causing mutations have been identified in TMEM67, particularly within the cleavage motif region, which can significantly impact antibody binding and experimental outcomes:

Common pathogenic variants affecting antibody recognition:

• F343V, K329T, and L349S variants located within the cleavage motif can alter protein conformation and epitope accessibility .

• These mutations may prevent proper ADAMTS9-mediated cleavage, resulting in accumulation of the non-cleaved form .

Experimental design considerations:

• When studying patient samples or model systems with these mutations, use multiple antibodies targeting different epitopes to ensure detection.

• Include domain-specific constructs as controls to validate recognition patterns in the context of mutations.

• Consider the potential impact of mutations on post-translational modifications, particularly glycosylation, which is known to occur in TMEM67 and may affect antibody binding .

For quantitative comparisons between wild-type and mutant TMEM67, establish standard curves with recombinant proteins containing the relevant mutations to account for potential differences in antibody affinity.

What are the optimal approaches for studying TMEM67 in the ciliary transition zone?

The ciliary transition zone presents unique challenges for antibody-based detection due to its complex molecular architecture:

Fixation and permeabilization optimization:

• For transition zone-specific markers, ice-cold methanol fixation for 5 minutes at −20°C is superior to paraformaldehyde fixation .

• Consider pre-extraction with detergents like 0.1% Triton X-100 before fixation to remove soluble proteins and improve signal-to-noise ratio at the transition zone.

Co-localization strategies:

• Use super-resolution microscopy techniques (STED, STORM, SIM) to resolve the precise localization of TMEM67 within the 200-300nm transition zone.

• Co-stain with established transition zone markers like NPHP1, NPHP4, or CEP290 to confirm proper localization.

• Employ multiple fluorescence channels to distinguish between the axoneme, transition zone, and basal body components.

Temporal considerations:

• Study TMEM67 localization during different stages of ciliogenesis by using time-course experiments after serum starvation .

• For live-cell imaging, consider using split-GFP or HaloTag fusion constructs of TMEM67 that minimize interference with protein function.

In C. elegans models, TMEM67 homologues can be studied in relation to other transition zone proteins like NPHP-4, providing evolutionary context to mammalian studies .

How should TMEM67 antibodies be applied in ciliopathy research?

Ciliopathies associated with TMEM67 mutations, particularly Meckel-Gruber syndrome and Joubert syndrome, present unique opportunities for antibody-based studies:

In patient samples:

• Use immunohistochemistry to assess TMEM67 expression patterns in affected tissues like kidneys, liver, and brain, which commonly show abnormalities in ciliopathies .

• Compare subcellular localization of wild-type and mutant TMEM67 to determine if pathogenic variants affect protein trafficking to the ciliary transition zone.

• Evaluate ciliary morphology in patient-derived cells using co-staining of TMEM67 with ciliary markers.

In model systems:

• The Tmem67 tm1Dgen/H1 knockout mouse model shows phenotypes closely resembling those seen in Wnt5a and Ror2 knockout mice, including pulmonary hypoplasia, ventricular septal defects, body axis shortening, and cochlear defects .

• These models enable analysis of how TMEM67 deficiency affects tissue-specific development and ciliary functions.

When quantifying ciliary defects in patient samples or model systems, establish consistent scoring criteria for ciliary number, length, and transition zone integrity to ensure reproducible results across laboratories.

What are the critical methodological considerations for co-immunoprecipitation studies with TMEM67?

TMEM67 interacts with several proteins, including ROR2, making co-immunoprecipitation (co-IP) studies valuable for understanding its functional complexes:

Antibody selection for co-IP:

• Choose antibodies targeting epitopes that are not involved in protein-protein interactions to avoid disrupting complexes of interest.

• For studying TMEM67-ROR2 interactions, antibodies against the intracellular domains may be preferable since the extracellular domains are involved in the interaction .

Buffer optimization:

• For membrane protein complexes like TMEM67-ROR2, use mild detergents (0.5-1% NP-40 or Digitonin) to solubilize membranes while preserving protein-protein interactions.

• Include protease inhibitors to prevent degradation of the full-length protein and phosphatase inhibitors when studying phosphorylation-dependent interactions, such as ROR2 phosphorylation following Wnt5a stimulation .

Experimental design considerations:

• For studying dynamics of TMEM67-ROR2 interaction, perform time-course experiments after Wnt5a stimulation.

• Include ADAMTS9 knockout cells as a control to assess how prevention of TMEM67 cleavage affects its interaction with binding partners .

• Consider cross-linking approaches to stabilize transient interactions before lysis and immunoprecipitation.